Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
AstraZeneca
McKinsey
Johnson and Johnson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CC-220

See Plans and Pricing

« Back to Dashboard

What is the drug development status for CC-220?

CC-220 is an investigational drug.

There have been 10 clinical trials for CC-220. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Liver Diseases, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Celgene Corporation, Celgene, and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and two hundred and thirty-five international patents.

Recent Clinical Trials for CC-220
TitleSponsorPhase
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsCelgenePhase 1
Radiolabeled Study of CC-220 in Healthy Male SubjectsCelgenePhase 1
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus ErythematosusCelgenePhase 2

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220
Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-220   Start Trial Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CELGENE CORPORATION (Summit, NJ)   Start Trial
CC-220   Start Trial Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same Celgene Corporation (Summit, NJ)   Start Trial
CC-220   Start Trial 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus Celgene Corporation (Summit, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-220

Drugname Country Document Number Estimated Expiration Related US Patent
CC-220 Australia 2015305449 2034-08-22   Start Trial
CC-220 Brazil 112017003620 2034-08-22   Start Trial
CC-220 Canada 2958867 2034-08-22   Start Trial
CC-220 Chile 2017000416 2034-08-22   Start Trial
CC-220 China 107073115 2034-08-22   Start Trial
CC-220 Eurasian Patent Organization 201790439 2034-08-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Moodys
Mallinckrodt
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.